The implants have been developed for use in breast reconstruction, augmentation and revision surgery.

Allergan board chairman and CEO David Pyott said: "The FDA approval of additional Natrelle 410 shaped gel implants underscores Allergan’s long-standing commitment to innovation and R&D investment in medical aesthetics and plastic surgery.

"The approval provides plastic surgeons with additional implant options enabling them to better meet the individual needs of women considering breast augmentation, reconstruction or revision surgery."

The FDA approval was based on 10-year data from a study of around 1,000 women who underwent breast reconstruction, augmentation or revision surgery with the previously approved range of Natrelle 410 breast implants.

The new styles will allow surgeons to customize their patients’ fit by matching the implant’s height and width with the patient’s body type while providing optimal projection, based on the desired aesthetic outcome.

According to the company, the new Natrelle 410 X styles provide extra protection, while the new L styles feature low height and low projection.